NCT01500863 (ERAMAD) is a Phase 4 clinical trial of hCG in Ovarian Hyperstimulation Syndrome, sponsored by IVI Madrid.

Who is sponsoring NCT01500863?

NCT01500863 is sponsored by IVI Madrid.

What drugs are being tested in NCT01500863?

Interventions in NCT01500863: hCG, triptorelin, Triptorelin, estradiol valerate, micronized vaginal progesterone, triptorelin, hCG, triptorelin, hCG, triptorelin, recombinant LH.

What condition does NCT01500863 study?

NCT01500863 studies Ovarian Hyperstimulation Syndrome.

Is NCT01500863 still recruiting?

NCT01500863 is currently completed. Last updated 25 October 2016.

Last reviewed 2016-10-25 · How we verify

NCT01500863: ERAMAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endometrial Receptivity After GnRH Agonist Triggering From Final Oocyte Maturation

Completed Phase 4 Last updated 25 October 2016

What this trial tests

Phase 4 trial testing hCG in Ovarian Hyperstimulation Syndrome in 35 participants. Completed.

Timeline

1 November 2011

Primary endpoint
1 May 2012

Quick facts

Lead sponsor	IVI Madrid
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	single
Primary purpose	treatment
Enrollment	35
Start date	1 November 2011
Primary completion	1 May 2012
Sites	1 location across Spain

Drugs / interventions tested

hCG
triptorelin (triptorelin) — full drug profile →
Triptorelin, estradiol valerate, micronized vaginal progesterone — full drug profile →
triptorelin, hCG
triptorelin, hCG
triptorelin, recombinant LH — full drug profile →

Conditions studied

Ovarian Hyperstimulation Syndrome — all drugs for Ovarian Hyperstimulation Syndrome →

Sponsor

IVI Madrid — full company profile →

Who can join

Adults 18 to 35, female only, with Ovarian Hyperstimulation Syndrome. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

endometrial receptivity gene expression profile
Time frame: participants will be followed for the duration of the cycle, an expected average of 4 weeks

Sponsor's own description

Conventional luteal phase support after human chorionic gonadotrophin (hCG) triggering in women undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) provides adequate pregnancy rates and live birth rates, but Ovarian hyperstimulation syndrome (OHSS) still occurs in 1-3% of the patients. If gonadotropin-releasing hormone agonist (GnRHa) are used instead of hCG, OHSS does not occur, but clinical results are somehow diminished. By testing different luteal support protocols on women undergoing GnRHa triggering, the investigators aim to find out which protocol resembles the most the gene expression profile observed after hCG triggering and conventional luteal phase support, in order to choose it as the most adequate in terms of endometrium receptivity and safety (OHSS incidence).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of hCG

Trials testing the same drug.

NCT07028710 — Early Luteal Phase Progesterone Kinetics After hCG-Induced Ovulation in Modified Natural Cycle · NA · not yet recruiting
NCT05123040 — Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids · Phase 1, PHASE2 · terminated
NCT06091436 — To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FS · Phase 3 · completed
NCT06684951 — Effects of Intrauterine Flushing With Human Chorionic Gonadotropin on ICSI Outcome · Phase 4 · completed
NCT05838105 — Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates · NA · unknown

Other IVI Madrid trials

Trials by the same sponsor.

NCT06244745 — Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors. · Phase 3 · recruiting
NCT05606679 — Maternal KIR and Fetal HLA Influence Reproductive Success in ART-oocyte Donor. · unknown
NCT05508217 — Impact of Telomere Biology and Sperm DNA Fragmentation on Embryonic Development · unknown
NCT02718105 — Maternal and Fetal Compatibility in Assisted Reproductive Technology (ART)-Oocyte Donor Influences Live Birth Rate · completed
NCT04778358 — Higher Dose of Rekovelle in Oocyte Donors · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01500863 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IVI Madrid
Last refreshed: 25 October 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01500863.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing